Tami Zakaria, head of construction equity research at JPMorgan, joins ‘Money Movers' to discuss Caterpillar as the industrial giant becomes the best-performing stock in the Dow this year.

CNBC's MacKenzie Sigalos reports on Meta's acquisition of intelligent-agent firm Manus.

LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before February 9, 2026.

WAB's growing backlog and aggressive shareholder returns are lifting its performance, helping the stock beat its industry and surge over the past year.

OMC shares have risen 11.7% over the past month, outperforming its industry. Rising estimates, earnings beat history and growth outlook indicate more upside.

COTY's e-commerce grew mid-single digits in the fiscal first quarter, reaching 20% of sales as digital execution improves and online demand stays resilient.

Shell plc (the ‘Company') announces that on 30 December, 2025 it purchased the following number of Shares for cancellation.

Besides Nvidia, Wedbush's Dan Ives recommended three other “Magnificent Seven” stocks to play the AI trade, plus a “cult” stock and a software company.

Nvidia is in advanced talks to buy Israel-based AI startup AI21 Labs for as much as $3 billion, the Calcalist financial daily reported on Tuesday.

Defiance Quantum ETF captured the quantum computing theme at the right time, attracting massive investor interest and growing to roughly $3 billion in assets after a powerful run, but that success also. The QTUM ETF offers diversified, not pure-play, exposure to quantum computing through a broad mix of mega-cap technology firms and smaller R&D-driven companies, which reduces single-stock risk but also limits upside. A potential pullback in 2026 would be healthy rather than thesis-breaking.

BABA faces margin pressure as e-commerce competition intensifies, with profits plunging despite revenue growth and heavy AI and logistics spending.

AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.

Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.

Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, but Animal Health growth, pipeline depth, and margin strength offer diversification and optionality. Even in conservative scenarios, MRK could deliver ~7% annualized returns, with potential for double-digit upside if new drugs succeed and margins improve.

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Tuesday.

One of the key investing stories to watch in 2026 is the potential for a SpaceX IPO, an offering that was confirmed by the company's CEO Elon Musk. A market expert shares with Benzinga what the IPO could mean for a bull run, other IPOs and Tesla Inc (NASDAQ: TSLA) investors.

HIG is up nearly 27% in a year as earnings, revenue growth and capital returns power the rally, but leverage and Personal Insurance risks still linger.

Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.

Ed Butowsky thinks Meta Platforms' (META) acquisition of Manus is a “brilliant move.” He discusses Manus's ties to China and Singapore and potential regulatory scrutiny.

LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 12, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX) securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR FREEPORT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.